

RECEIVED
CENTRAL FAX CENTER

001/013

MAY - 4 2004

OFFICIAL

Atty Docket No. 015280-356100US

PTO FAX NO.: 703 872 9305

ATTENTION: Examiner Zeman, Robert A.

Group Art Unit 1645

OFFICIAL COMMUNICATION
FOR THE PERSONAL ATTENTION OF
EXAMINER Zeman, Robert A.

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following document(s) in re Application of PASTAN et al., Application No. 09/673,707, filed January 11, 2001 for RECOMBINANT IMMUNOTOXIN DIRECTED AGAINST THE HIV-1 GP120 ENVELOPE GLYCOPROTEIN is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Document(s) Attached

1. Transmittal Form
2. Amendment

Number of pages being transmitted, including this page: 13Dated: 5-4-04Lucene Rodon

PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 576-0300

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, CA 94111-3834
Telephone: 415-576-0200
Fax: 415-576-0300


60208715 v1


*Received in Central
Fax 6/17/04*

PTO/SB/21 (08-03)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	09/673,707
		Filing Date	January 11, 2001
		First Named Inventor	Pastan, Ira H.
		Art Unit	1645
		Examiner Name	Zeman, Robert A.
Total Number of Pages in This Submission		Attorney Docket Number	015280-356100US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual	Townsend and Townsend and Crew LLP Laurence J. Hyman	Reg. No. 35,551
Signature		
Date	5/4/04	

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Fax No. (703) 872 9305 on		
Typed or printed name	Irene Rodas	
Signature		Date 5-4-04

60208753 v1

MAY - 4 2004

003/013

OFFICIAL

I hereby certify that this correspondence is being facsimile
transmitted to the United States Patent and Trademark Office,
Fax No. 1-703-305-9306 on 5-4-04

PATENT
Attorney Docket No.: 015280-356100US
Client Ref. No.: E-201-1998/0-US-06

TOWNSEND and TOWNSEND and CREW LLP

By: *Sam Rodas*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PASTAN et al.

Application No.: 09/673,707

Filed: January 11, 2001

For: RECOMBINANT IMMUNOTOXIN
DIRECTED AGAINST THE HIV-1
GP120 ENVELOPE GLYCOPROTEIN

Customer No.: 20350

Confirmation No. 3958

Examiner: Zeman, Robert A.

Technology Center/Art Unit: 1645

AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed April 26, 2004, please enter the following
amendments and remarks:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this
paper.

Remarks/Arguments begin on page 10 of this paper.